Henoch-Schonlein Purpura in a Patient with Ankylosing Spondylitis after Infliximab Therapy.
- Author:
Woo Jin JUNG
1
;
Yoon Jeong NAM
;
Seung Geun LEE
;
Ji Min KIM
;
Margaret SONG
;
Moon Bum KIM
;
Geun Tae KIM
Author Information
1. Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea. sglee@pnuh.co.kr
- Publication Type:Case Report
- Keywords:
Ankylosing spondylitis;
Henoch-Schonlein purpura;
Tumor necrosis factor-alpha inhibitor
- MeSH:
Abdominal Pain;
Antibodies, Monoclonal;
Arthritis, Rheumatoid;
Biopsy;
Humans;
Ileum;
Jejunum;
Leg;
Male;
Purpura;
Purpura, Schoenlein-Henoch;
Skin;
Spondylitis, Ankylosing;
Systemic Vasculitis;
Tumor Necrosis Factor-alpha;
Vasculitis;
Vasculitis, Leukocytoclastic, Cutaneous
- From:Korean Journal of Medicine
2013;84(5):764-768
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tumor necrosis factor alpha (TNF-alpha) inhibitors are used widely to treat patients with active rheumatoid arthritis and ankylosing spondylitis (AS). Although various cutaneous reactions can occur as side effects of TNF-alpha inhibitors, systemic vasculitis requiring withdrawal of the agent and immunosuppressive drugs is rare. A 59-year-old male with AS who had been treated with infliximab for 60 months visited us with complaints of palpable purpura on both legs and severe abdominal pain. Abdominal computed tomography showed diffuse wall thickening of the proximal jejunum and ileum and a skin biopsy revealed leukocytoclastic vasculitis. The patient was diagnosed with Henoch-Schonlein purpura (HSP). Infliximab was discontinued and systemic steroid therapy at 0.5 mg/kg resulted in prompt resolution of the HSP. Here, we report the first case of HSP in a patient with AS after infliximab treatment.
